Aim: Individuals at clinical high risk for psychosis (CHR) exhibit neurocognitive deficits in multiple domains. The aim of this study is to investigate whether several components of neurocognition are predictive of conversion to psychosis.
INTRODUCTION
Previous studies have shown that individuals who are at clinical high risk (CHR) for psychosis have overall neurocognitive impairment compared with healthy controls (HC), [1] [2] [3] [4] [5] [6] including deficits in attention, 3, 5, 7 verbal memory, 1, 3, 5, [7] [8] [9] processing speed, 3, 5, 8, 9 working memory 1, 5, 7, 8, 10 and executive functioning. 1, 2, 5, 8 Moreover, a number of longitudinal studies have identified several baseline neurocognitive deficits that are predictive of conversion to psychosis, including verbal memory 1, 3 and an overall impaired cognition in comparison with non-converters. [2] [3] [4] The first aim of this study was to examine the baseline neurocognitive functioning of individuals at CHR for psychosis at the Center of Prevention and Evaluation (COPE), a research clinic working with CHR individuals at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI). The second aim of this study was to compare converters (CHR+) with nonconverters (CHR−). Our first hypothesis was that CHR individuals would have baseline neurocognitive impairments across all domains tested. Second, we hypothesized that the CHR+ subgroup would perform more poorly than CHR− individuals.
METHODS

Participants
Subjects were recruited via the Internet (copeclinic.org), brochures and mailings to clinicians and schools, presentations throughout the New York City metropolitan area and from other programmes within Columbia University/NYSPI. We recruited subjects aged 13-30 who met CHR criteria as assessed by the Structured Interview for Psychosis Risk Syndromes (SIPS). 11 Participants were recruited between the period of April 2009 and April 2014.
Exclusion criteria included a history of psychotic symptoms beyond BIPS criteria (e.g. schizophrenia). Participants were also excluded if their symptoms were better accounted for by a non-psychotic diagnosis (e.g. borderline personality disorder), or if their symptoms only occurred in the context of substance use. Further, participants with an IQ <70 or any medical or neurological disorder that could significantly affect functioning of the brain were excluded. Subjects were also excluded if they were acutely suicidal or homicidal and needed emergent care. COPE's patients are primarily referred from academic counselling centres and mental health professionals throughout the tri-State area, which included New York state, New Jersey and Connecticut. We included 52 CHR participants for this study. Subjects received longitudinal follow-up for 2.5 years (range: 1-5 years) to determine conversion status, which was assessed by face-to-face interview on a trimonthly basis using the SIPS.
An external normative healthy control group (EN-HC) was included for our calculation of CHR z-scores on neurocognitive assessments. 12, 13 These participants were recruited by advertisement and they received compensation for participation in the study. Exclusion criteria were a history of any psychiatric conditions including substance use disorders, neurological diseases and major medical illness.
The Institutional Review Board at NYSPI approved this study. Before beginning any research, informed consent was obtained (informed assent and parental consent if the participant was under 18 years of age).
Assessments
Demographic information was acquired at baseline. The demographic questionnaire administered prior to the neurocognitive assessments prompted participants to choose from the following options for education level: completed less than high school, high school, technical, some college, BA/BS or graduate school. Adjustment for education level for the neurocognitive assessments required a number of years of education. Therefore, the numbers of years of education were estimated for some of the participants. The following estimates were used: 10 years of education for 'less than high school', 12 years for 'high school', 13.5 years for 'technical', 14 years for 'some college', 16 years for 'BA/BS' and 18 years for 'graduate level'.
Our neurocognitive battery assessed the following domains of neurocognitive functioning: executive functioning (computerized Stroop), attention (Continuous Performance Test-Identical Pair (CPT-IP)), working memory (computerized N-Back), processing speed (choice reaction time (CHRT)) and reaction time (simple reaction time (SRT)). 12 During the SRT task, participants were instructed to react as fast as possible to visual stimuli. During the CHRT task, participants were instructed to detect in which of four boxes the stimulus was presented and to react according to specific task instructions.
The neurocognitive assessments were completed in a fixed order after subjects were assessed by the SIPS. The analysed variables are as follows: reaction time for the SRT and CHRT, the number of correct responses on the CHRT, d-prime (measures overall sensitivity) on CPT-IP and N-back and the interference score for Stroop.
Statistical analysis
Independent t-tests and chi-square analyses were used to assess demographic comparability between the CHR+ individuals and CHR− individuals. Subscores from SRT, CHRT, CPT-IP, N-back and Stroop were first converted into z-scores based on normative data and adjusted for gender, age and education, and then compared in the same fashion. The scores were adjusted based on regression formulas from the EN-HC sample. Each variable had various weights for age, sex and education to create a predicted score. The predicted score was then subtracted from the actual score and divided by the standard deviation (SD) of the sample within various age groups. 12, 13 Group comparisons of the neurocognitive tests were carried out with independent t-tests based on the normative-adjusted z-scores. The CHR z-scores were based on the EN-HC; therefore, the z-score of the EN-HC group was 0 with an SD of 1. An index of overall neurocognitive performance was calculated by converting each z-score to a negative value and then averaging these values for each participant on the six subscores.
Higher positive z-scores for SRT, choice reaction time-reaction time (CHRT-RT) and Stroop indicate poorer performance. Lower negative z-scores for choice reaction time-numbers correct (CHRT-NC), CPT-IP, N-back and overall performance indicate poorer performance.
RESULTS
Demographics and clinical characteristics of the participants are summarized in Table 1 . Group comparisons between CHR+ and CHR− revealed no significant differences for age (P = 0.13) and gender (χ 2 (1) = 0.29, P = 0.59), but did reveal a significant difference for years of education (P = 0.008; CHR− > CHR+). We estimated the years of education for 18 of the 52 participants (34.6%). During followup, 14 CHR participants (26.9%) converted to psychosis within 9.8 (SD = 8.0) months on average, with a range of 1-32 months and median 9 months ( Supplementary Fig. S1 ). Of the CHR+, eight converted to schizophrenia, two to a schizoaffective disorder, two to psychotic disorder NOS, one had a delusional disorder and the diagnosis of one CHR+ was missing. One of the CHR+ participants had missing time to conversion data and the diagnosis of one CHR+ is unknown. After correcting for multiple comparisons, group comparisons between CHR+ and CHR− showed no baseline differences in positive, negative or disorganized symptoms or symptoms of general psychopathology; there were also no baseline differences in social and occupational functioning, as assessed by the Global Assessment of Functioning (modified scale).
Of the 52 CHR participants, two did not have CPT-IP data and one had missing N-back data. There was one extreme outlier (>50 SD) on the Choice RT number of correct answers, which was also omitted from the analysis. Consequently, the baseline CPT-IP consisted of 50 measurements, the N-back of 51 and the Choice RT number correct consisted of 51 measurements, instead of 52. Table 2 shows the results of the neurocognitive measures for the different CHR groups. Overall, CHR individuals performed significantly worse on all measures in comparison with the EN-HC: SRT (P < 0.0001), CHRT-RT (P < 0.0001), CHRT-NC (P < 0.02), CPT-IP (P < 0.001), Stroop (P < 0.005), N-back (P < 0.02) and overall (P < 0.0001). There were no significant differences between the CHR+ and CHR− participants after correcting for multiple comparisons (Bonferroni). CHR+ individuals performed more poorly than the CHR− individuals on the SRT, CHRT-RT, CHRT-NC, N-back and on overall neurocognitive performance. CHR− individuals performed more poorly than CHR+ individuals on the Stroop and CPT-IP (see Figure 1 for the neurocognitive profile of the CHR groups).
DISCUSSION
The aim of this study was to determine whether neurocognitive functioning is predictive of conversion to psychosis. Our results indicate that our CHR cohort had cognitive impairments similar to what has been reported in other CHR samples. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, none of the neurocognitive domains assessed at baseline (reaction time, processing speed, executive functioning, working memory, attention and overall performance) were significantly different between subjects who converted to a psychotic disorder and subjects who did not. This finding is consistent with prior findings for executive functioning and working memory in CHR subgroups. 8, 14 Our study was limited by its small sample size and modest conversion rate, both of which decrease the power of this study. The low conversion rate could be due to the help-seeking nature of COPE's participants; most participants were referred from academic (school-based) settings and private clinicians for early assessment and potential intervention. Additionally, we did not examine performance on all neurocognitive domains, such as verbal memory, which has been shown to most consistently predict conversion in comparison with other domains that have more variable predictive power. 4, 15 In addition, although our hypotheses were made a priori to the analysis, the participants were not specially recruited for neurocognitive assessment and not all subjects recruited by COPE received the neurocognitive battery. As a result our sample was small and was not recruited to observe an effect on neurocognitive performance.
In summary, consistent with the literature, the CHR population did show overall neurocognitive deficits compared with the healthy control external comparison group. We did not find a significant neurocognitive predictor for conversion in this study.
